Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Prostatic Neoplasms 9Neoplasms 9Lung Neoplasms 6Endometrial Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 4Oropharyngeal Neoplasms 4Colorectal Neoplasms 4Pathologic Complete Response 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2Meningioma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leiomyoma 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2Carcinoma, Basal Cell 2Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Trauma, Nervous System 1

Interventions

Carboplatin 5pembrolizumab 3Paclitaxel 3Observation 3Capecitabine 3Azacitidine 3venetoclax 2pertuzumab 2olaparib 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Oxaliplatin 2Irinotecan 2Immunotherapy 2Chemoradiotherapy 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tegafur-gimeracil-oteracil 1taxane 1talazoparib 1tagraxofusp 1sarilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pathologic Complete Response × Observation × 1 year × Clear all
NCT06743555 2026-04-28

SAVED LUNG

Centre hospitalier de l'Université de Montréal (CHUM)

Phase 1 Not yet recruiting
14 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07353840 2026-01-20

T-START-CR

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Recruiting
160 enrolled
Lymphoid

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡